Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.

Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.

Researchers have designed a candidate drug that could help make pancreatic cancer, which is almost always fatal, a treatable, perhaps even curable, condition. Scientists discover a new way to disarm a ...

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement ...

Four international centers contributed 237 KA or cSCC tumor samples from patients receiving an RAF inhibitor (either vemurafenib or sorafenib; n = 19) or immunosuppression therapy (n = 53) or tumors ...